HOME >> BIOLOGY >> NEWS
Cell pathways' SAANDs compounds enhance antitumor effects of Taxol™ in rodent models of breast cancer

HORSHAM, PA (April 3, 2000) -- CP461, a second generation selective apoptotic antineoplastic drug (SAAND) compound, under development by Cell Pathways, Inc. (Nasdaq: CLPA), significantly enhanced the anti-tumor activity of Taxol™ (paclitaxel) in a classic mouse model of human breast cancer, according to a presentation by company scientists this week at the annual meeting of the American Association for Cancer Research (AACR).

Cell Pathways researchers implanted human breast tumor cell lines in immunosuppressed (nude) mice and divided them into treatment and control groups. The treated mice were divided into multiple groups receiving either (1) five days of intravenous paclitaxel alone, (2) 14 days of oral CP461 at a subtherapeutic dose based on previous single agent studies, or (3) the drugs in combination. The researchers then observed the mice for 45 days. The mice tolerated the drug treatments well, whether they received the single agents or combination therapy, and there were no differences in unscheduled deaths or weight loss between the groups. The researchers observed that the reduction in the size of the tumors achieved by the combination of paclitaxel and CP461 was significantly greater (p=0.03) than that achieved with paclitaxel alone during treatment and during the month after discontinuation of treatment.

"This research suggests that CP461, given in combination with paclitaxel, may potentially increase paclitaxel1s efficacy in breast cancer without adding any additional side-effects," said Rifat Pamukcu, M.D., chief scientific officer of Cell Pathways. "CP461 is nearing completion of a Phase Ib safety study as a single agent in cancer patients. Based on these preclinical results, we plan to investigate CP461 as a single agent cancer therapy and in combination cancer chemotherapeutic studies in the near future."

CP461 is a second generation SAAND based on the mechanism of action of Aptosyn (exisulind). Aptosyn™ i
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
2-Apr-2000


Page: 1 2

Related biology news :

1. Aptosyn™ (exisulind) and other SAANDs target early event in cancer; AACR presentations detail novel apoptotic pathway
2. Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms
3. Scientists identify compounds that mimic calorie restriction
4. New, non-radioactive screen for antimalarial compounds
5. Three molecular-targeted compounds show promise against cancers
6. Emory scientists find anti-tumor compounds in magnolia cones
7. Mouse model links alcohol intake to marijuana-like brain compounds
8. Iron-binding compounds decrease body odor
9. New evidence for organic compounds in deep space
10. Researchers identify compounds that might help in spinal cord repair
11. Selected estrogen compounds modify risks of vein clotting, a response to hormone replacement theraphy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
Breaking Biology Technology:
Cached News: